Route 66 Endometrial Cancer SPORE

66 号公路子宫内膜癌孢子

基本信息

批准号：
10711634
负责人：
DORIS Mangiaracina BENBROOK
金额：
$ 238.47万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-23 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10711634
关键词：
Address Affect Aftercare Atypical Endometrial Hyperplasias Bioinformatics Biological Biological Markers Biological Process Biometry Biopsy Body Weight decreased Cancer Biology Cancer Model Cancer Patient Cancer Science Clinical Clinical Trials Collaborations Combination Drug Therapy Communities Complement Data Data Analyses Death Rate Dedications Development Disease Drug Kinetics Early Diagnosis Endometrial Carcinoma Endometrial Hyperplasia Enrollment Ensure Equity Fertility Fostering Funding Future Genes Goals Health Sciences Heat shock proteins Histology Immunohistochemistry Immunologics Incidence Individual Institution Malignant Female Reproductive System Neoplasm Malignant Neoplasms Malignant neoplasm of cervix uteri Malignant neoplasm of ovary Marriage Measures Mentors Metabolic Minority Molecular Molecular Chaperones Mutation New Mexico Obesity Oklahoma Pathologic Pathology Patient-Focused Outcomes Patients Population Sciences Premenopause Prevention Prevention strategy Primary Prevention Progestins Proteins Recurrence Research Research Personnel Research Priority Research Project Grants Research Support Resources Route Scientist Specialized Program of Research Excellence Specimen Standardization TP53 gene Testing Therapeutic Translational Research Tumor Biology Underrepresented Minority Underrepresented Populations United States Universities Uterus Washington Woman Work angiogenesis anticancer research axl receptor tyrosine kinase behavior test biobank cancer therapy career clinical practice design drug development early phase clinical trial effective therapy fluorescence imaging forging improved inhibitor innovation interest member metabolomics molecular marker novel novel drug combination novel marker novel strategies novel therapeutics pre-clinical preservation prevent programs recruit response response biomarker stable isotope therapy outcome translational research program translational study treatment response treatment strategy virtual

项目摘要

PROJECT SUMMARY The Route 66 Endometrial Cancer SPORE brings together interactive research teams from three institutions to create a dynamic translational research program aimed at developing and testing new strategies to prevent and treat endometrial cancer. This SPORE includes three research projects; an administrative core; a biostatistics and bioinformatics core; a biospecimens, metabolomics, and pathology core; and developmental research and career enhancement programs. The three projects, chosen and refined with extensive input from our internal and external advisory boards, are designed to have significant potential to change clinical practice within five years. Project 1: HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy. Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer. Project 3: Improving Primary Prevention and Uterine Preservation in Premenopausal Women with Obesity and Endometrial Hyperplasia. Projects 1 and 2 are clinical/translational projects, whereas Project 3 is an early detection, prevention, or population science project. All three projects include clinical trials and represent carefully chosen marriages between selected endometrial cancer research priorities and the strengths of Washington University in St. Louis and our collaborators at the University of New Mexico and the University of Oklahoma Health Sciences Center. The overall aims of our SPORE are to 1) Test promising new therapies to treat or prevent endometrial cancer; 2) Elucidate the key biologic processes that drive endometrial cancer and develop novel biomarkers to predict development of endometrial cancer and response to therapies; 3) Leverage and enhance capacities of shared research resources; 4) Recruit and mentor new investigators and support innovative ideas in translational endometrial cancer research; 5) Facilitate collaboration of those interested in endometrial cancer research; and 6) Ensure equitable enrollment in clinical trials and involvement of diverse community members and investigators in research. In completing the work proposed here, we will test three new strategies to prevent or treat endometrial cancer. Future work can be directed at moving the most promising treatment approaches into larger trials. Additionally, we will obtain an unprecedented level of molecular, cellular, immunologic, and metabolomic detail regarding endometrial cancer and response to treatment, which will likely lead to development of additional novel clinical trials. Finally, by developing new ideas, investigators, and collaborations, we will expand the breadth and depth of research aimed at treating or preventing endometrial cancer.

项目摘要 66号公路子宫内膜癌孢子将互动研究团队从三个机构到创建一个动态的转化研究计划，旨在制定和测试新策略以防止并治疗子宫内膜癌。该孢子包括三个研究项目；行政核心；一个生物统计学和生物信息学核心；生物测量，代谢组学和病理学核心；和发展研究和职业增强计划。从中选择和完善的三个项目都以广泛的投入我们的内部和外部咨询委员会旨在改变临床实践的巨大潜力五年之内。项目1：晚期和复发性子宫内膜癌疗法中的HSPA蛋白。项目2：抑制AXL以改善子宫内膜癌的治疗反应。项目3：改善初级肥胖和子宫内膜增生的绝经前妇女的预防和子宫保存。项目1和2是临床/翻译项目，而项目3是早期检测，预防或人口科学项目。这三个项目包括临床试验并代表精心挑选的婚姻在选定的子宫内膜癌研究重点和华盛顿大学的优势之间路易斯和我们在新墨西哥大学和俄克拉荷马大学健康科学的合作者中心。我们孢子的总体目的是1）测试有希望的新疗法以治疗或预防子宫内膜癌症; 2）阐明驱动子宫内膜癌并发展新生物标志物的关键生物学过程预测子宫内膜癌的发展和对疗法的反应； 3）杠杆和增强能力共享研究资源； 4）招募和指导新的研究人员，并支持创新思想翻译子宫内膜癌研究； 5）促进对子宫内膜癌感兴趣的人的合作研究; 6）确保在临床试验和不同社区成员的参与中公平入学和研究人员。在完成此处提出的工作时，我们将测试三种新策略预防或治疗子宫内膜癌。未来的工作可以致力于移动最有前途的治疗进入更大的试验。此外，我们将获得前所未有的分子，细胞，有关子宫内膜癌和对治疗反应的免疫学和代谢组细节，这可能很可能导致开发其他新型临床试验。最后，通过开发新的想法，调查人员和合作，我们将扩大旨在治疗或预防子宫内膜的研究的广度和深度癌症。